stockportfolio.pro
Stocks / KRYS vs NUVL
KRYS vs NUVL
Krystal Biotech, Inc. and Nuvalent, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Krystal Biotech, Inc. (KRYS) | Nuvalent, Inc. (NUVL) | |
|---|---|---|
| Market cap | $9.2B | $9.8B |
| Revenue (latest FY) | $389.13M | $0 |
| Net income (latest FY) | $204.83M | $-425.38M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | 52.6% | — |
| Return on equity | 16.8% | -34.1% |
| P/E ratio | 42.0 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 0 |
| Positive free cash flow | Yes | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open KRYS — free Open NUVL — freeFrequently asked questions
Which is bigger, KRYS or NUVL?
Nuvalent, Inc. is larger by market capitalization — $9.8B versus $9.2B.
Which grows faster, KRYS or NUVL?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.